BS_YEW22W35
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 14.388961892247043
- age_years
- 14.844
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.649
- G2M_CHECKPOINT+0.544
- SPERMATOGENESIS+0.330
- MYC_TARGETS_V2+0.309
- MYC_TARGETS_V1+0.250
- MITOTIC_SPINDLE+0.193
- INTERFERON_ALPHA_RESPONSE+0.114
- DNA_REPAIR+0.073
- FATTY_ACID_METABOLISM+0.066
- KRAS_SIGNALING_DN+0.026
Top 10 suppressed
- TGF_BETA_SIGNALING-0.437
- ALLOGRAFT_REJECTION-0.413
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.411
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.378
- TNFA_SIGNALING_VIA_NFKB-0.351
- MYOGENESIS-0.329
- INFLAMMATORY_RESPONSE-0.327
- IL6_JAK_STAT3_SIGNALING-0.319
- PROTEIN_SECRETION-0.314
- IL2_STAT5_SIGNALING-0.309
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303756 | — | — | 0.896 |
| 2 | SRR12202476 | — | — | 0.887 |
| 3 | C3N-02728 | — | cohortMD1 | 0.873 |
| 4 | TCGA-85-A510-01A-11R-A26W-07 | — | cohortA3 | 0.870 |
| 5 | C3N-02155 | — | cohortA3 | 0.868 |
| 6 | SRR8526719 | — | cohortMD1 | 0.864 |
| 7 | SRR650202 | — | — | 0.863 |
| 8 | SRR5088911 | — | — | 0.858 |
| 9 | TCGA-HN-A2NL-01A-11R-A18M-07 | — | E | 0.858 |
| 10 | 085e4228-8ed7-44d7-9ab5-8a096434b650 | — | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.649 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.544 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.330 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.309 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.193 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.114 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.073 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.066 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.026 | Remibrutinib | — uncovered |